Biotechnology

Bio Essence Corp Appoints Xiying (Thea) Zhang and Geoff Fellows as Independent Directors to Its Board

October 26, 2026 8:00 AM

Bio Essence Corp (OTCQB:BIOE) ("Bio Essence" or the "Company") today announced the appointment of Xiying (Thea) Zhang and Geoff Fellows to its Board of Directors as independent directors, effective October 19, 2026. The appointments expand the Board from three to five members, a majority of whom are now independent. Xiying (Thea) Zhang, CPIM, MBA, is Senior Supply Chain leader formerly with Oasis Pharmaceutical. She brings more than 15 years of...

Read more

Onyx BioLabs Peptides Reviews 2026 - Could This Be The Research Peptide Supplier You've Been Looking For?

October 26, 2026 7:20 AM

A published Certificate of Analysis (COA) gives a qualified laboratory buyer something concrete to examine before purchasing. It is still only a starting point. The questions that follow matter just as much. Does the report match the batch you are buying? What testing does it actually document? Can the issuing laboratory confirm it is real? This guide uses Onyx BioLabs' published materials as a worked example. It walks through five checks you...

Read more

RMTG's ISSCA Division Announces Successful Santa Cruz, Bolivia Conference, October 23-24

October 26, 2026 7:01 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, announces another successful ISSCA , its ISSCA division's regenerative medicine conference in Santa Cruz de la Sierra, Bolivia, this last weekend October 23-24 at Hotel Los Tajibos. The Santa Cruz conference extends ISSCA's Latin American physician-education...

Read more

Microbix Presenting at Planet MicroCap Investment Conference

October 26, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX, OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Planet MicroCap Toronto 2026 Investment Conference, powered by MicroCapClub and being hosted at the Arcadian Loft, 8th Floor, 401 Bay Street, Toronto, Ontario on October 27-29, 2026. During the conference, Microbix's CEO, Cameron Groome, will present and have one-on-one...

Read more

Path Fertility Awarded $2 Million NIH Grant to Develop Epigenetic Test for Severe Male Infertility and Associated Cancer Risk

October 26, 2026 6:08 AM

Path Fertility™, the commercial brand of Inherent Biosciences, Inc. and a molecular diagnostics company advancing epigenetic testing for male fertility, today announced it has received a Direct to Phase II Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH). The two-year award, totaling $2 million, will...

Read more

BioInvent's BI-1808 and KEYTRUDA(R) Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer

October 24, 2026 7:50 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced updated data from Part B of its ongoing clinical study of BI-1808, a first-in-class anti-TNFR2 antibody, combined with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced platinum-resistant recurrent ovarian cancer (PRROC) and a median of...

Read more

FluoGuide A/S Invites Investors to Q3 Webcast - Clinical Progress and the Road Ahead

October 23, 2026 8:45 AM

FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its interim report for Q3 2026 on Thursday, 26 November 2026, followed by a live investor webcast later the same day at 14:00 CET. CEO Morten Albrechtsen and CFO Ole Larsen will present the company's operational and financial results provide an update on key clinical developments, including the US pivotal trial of FG001 in high-grade glioma present upcoming milestones The webcast will be...

Read more

Biovica Announces Outcome Of The Rights Issue

October 23, 2026 4:45 AM

Biovica International AB (publ) ("Biovica" or the "Company")(STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) hereby announces the outcome of the Company's rights issue of B-shares with preferential rights for existing shareholders, in which the subscription period ended on 21 October 2026 (the "Rights Issue"). The outcome shows that approximately 49.97 percent of the shares offered have been subscribed for with subscription rights, approximately 21.14...

Read more

Vicore's Phase 2b ASPIRE Trial of Buloxibutid in IPF Passes Pre-Planned Futility Analysis and Remains on Track for Mid-2027 Topline Results

October 22, 2026 1:05 PM

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the independent Data Monitoring Committee (iDMC) for the Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis (IPF) recommended that the trial continue without modification following a pre-planned futility analysis. In parallel, the iDMC conducted...

Read more

RMTG's ISSCA Division Returns to São Paulo for a Second Brazil Congress, November 20-21

October 22, 2026 7:01 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a Regenerative Medicine Company. operating through its wholly owned subsidiary Global Stem Cells Group, today announced ISSCA 127, its ISSCA division's second São Paulo, Brazil congress of 2026, taking place November 20-21 in the city's Vila Olímpia district, following ISSCA's first 2026 Brazil program in April. Running two Brazil events in a single year is a...

Read more

VitroVivo Biotech LLC Highlights Tissue Analysis Capabilities for Biomedical Researchers Through Specialized Laboratory Services

October 22, 2026 2:50 AM

VitroVivo Biotech LLC, a Maryland-based provider of histology and molecular histopathology services, is highlighting its laboratory capabilities for researchers requiring detailed tissue examination, specialized cell isolation, and reliable specimen preparation. The company's service portfolio combines established histological procedures with advanced techniques used to investigate biological structures at the cellular and molecular levels....

Read more

Alligator Bioscience AB Reports Financial Results for The Period 1 January - 30 September 2026 and Provides a Business Update

October 22, 2026 2:20 AM

Alligator Bioscience (NASDAQ Stockholm:ATORX), a biotechnology company whose principal value driver is a financial interest in the HER2-targeting antibody programme HLX22, today announced its interim results for the third quarter of 2026 and provided a business update. "During the third quarter we refocused Alligator on its financial interest in HLX22, which is in global Phase 3 development at no development cost to Alligator, and carried out a...

Read more

eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research

October 21, 2026 4:30 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced that Chief Executive Officer, Michael Heltzen, will participate in a fireside chat hosted by Water Tower Research ("WTR") tomorrow, Thursday, October 22, 2026, at 11AM Eastern / 8AM Pacific Time. Moderated by Robert Sassoon, Managing Director of Healthcare, Emerging...

Read more

enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob Berman

October 21, 2026 8:44 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced the release of the third episode of its video series, "WTF with Rob Berman". The series gives investors real answers to what they need to know about enVVeno medical and why they need to know it. In the new episode, Rob Berman, CEO of enVVeno Medical, breaks down the total addressable market (TAM) for severe deep venous insufficiency (DVI), a condition...

Read more

Edison Oncology Appoints Michael Faber to Board of Directors and Announces Five Poster Presentations at Two Peer-Reviewed Oncology Meetings in November 2026

October 20, 2026 9:00 AM

Edison Oncology Holding Corp. ("Edison Oncology" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative small-molecule therapies by unlocking the potential of existing drugs and compounds for genetically defined cancers, today announced the appointment of Michael Faber to its Board of Directors. The Company also announced that five abstracts have been accepted for presentation at the 31st Annual Meeting of...

Read more

Lobe Sciences Appoints Tracy L. Goeken, M.D., as Chief Medical Officer

October 20, 2026 8:30 AM

Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company developing therapies for neurological conditions and rare diseases, today announced the appointment of Tracy L. Goeken, M.D., as Chief Medical Officer, effective October 20, 2026. Dr. Goeken most recently served as Chief Medical Officer at Linical, a global clinical research organization, where he led clinical development...

Read more

RMTG to Go Ringside at BKFC This Weekend to Capture Content for Its "RMTG Brief" Investor-Awareness Campaign

October 20, 2026 7:01 AM

Regenerative Medical Technology Group Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced that its content team will be ringside at this Saturday's Bare Knuckle Fighting Championship (BKFC) event to capture footage for "RMTG Brief," the Company's host-led investor-awareness and brand-visibility campaign. The on-site shoot is the latest...

Read more

Microbix Attending & Presenting at IPVS 2026

October 19, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending IPVS 2026 and presenting results of a novel synthetic vaginal matrix designed to assist with validation and ongoing quality management of HPV molecular assays used in cervical cancer screening programs. IPVS 2026 is the 38th annual conference of the International Papillomavirus Society, taking...

Read more

Faron to Report Final Melanoma Survival Data from the MATINS Study at ESMO 2026

October 19, 2026 2:30 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system, today announces that final results from the metastatic melanoma cohort of its Phase 1/2 MATINS study have been accepted as an ePoster at the European Society for Medical Oncology (ESMO) Congress 2026, taking place in Madrid, Spain, 23-27 October 2026....

Read more

BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026

October 18, 2026 6:40 PM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immunomodulatory antibodies, today announced the publication of an abstract ahead of its poster presentation at the ESMO Congress 2026 (European Society for Medical Oncology) in Madrid, October 23-27. The abstract reports previously communicated Phase 1/2a data (ASCO 2026) for BI-1808, a first-in-class anti-TNFR2 antibody, combined with MSD's...

Read more